Journal publications

Number of papers: 74
Number of first authorships: 24
Number of last authorships: 2
Total number of citations: 2245
H-index: 26

For a summary of research highlights instead, see this overview

Authors Title Journal Date PMID
Mahalingasivam V, Faucon AL, Sjölander A, Bosi A, González-Ortiz A, Lando S, Fu EL, Nitsch D, Bruchfeld A, Evans M, Wing K, Mansfield KE, Tomlinson L, Carrero JJKidney Function Decline After COVID-19 Infection.JAMA Netw Open202439724377
Tanaka S, Bosi A, Fu EL, Iseki K, Kitazono T, Hultgren R, Faucon AL, Carrero JJKidney Function, Kidney Function Decline, and the Risk of Abdominal Aortic Aneurysm: The Stockholm CREAtinine Measurements (SCREAM) Project.Eur J Vasc Endovasc Surg39706328
Ballew SH, Sang Y, Coresh J, Fu EL, Nitsch D, Carrero JJ, Grams MEIncorporation of Cystatin C Testing in Clinical Practice: Real World Experience in Sweden.Kidney Int Rep202439698352
Loureiro Harrison L, Fu EL, Thomson PC, Traynor JP, Mark PB, Stoumpos SImpact of arteriovenous fistula formation on trajectory of kidney function decline: a target trial emulation.Clin Kidney J202439687920
Heinen FJ, Peijster AJL, Fu EL, Kamp O, Chamuleau SAJ, Post MC, van der Stoel MD, Keyhan-Falsafi MA, van Nieuwkoop C, Klautz RJM, Tanis W, Cardiothoracic Surgery Registration Committee of the Netherlands Heart RegistrationExternal validation of EuroSCORE I and II in patients with infective endocarditis: results from a nationwide prospective registry.Eur J Cardiothorac Surg202439579090
Lambourg EJ, Fu EL, McGurnaghan S, Conway BR, Dhaun N, Grant CH, Pearson ER, Mark PB, Petrie J, Colhoun H, Bell S, Scottish Diabetes Research Network Epidemiology GroupStopping Versus Continuing Metformin in Patients With Advanced CKD: A Nationwide Scottish Target Trial Emulation Study.Am J Kidney Dis39521399
Bosi A, Xu Y, Faucon AL, Huang T, Evans M, Shin JI, Fu EL, Carrero JJHyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitors.Nephrol Dial Transplant39384578
Mazhar F, Faucon AL, Fu EL, Szummer KE, Mathisen J, Gerward S, Reuter SB, Marx N, Mehran R, Carrero JJSystemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease.Eur Heart J202439211962
Zoccali C, Tripepi G, Stel V, Fu EL, Mallamaci F, Dekker F, Jager KJDecoy receptors as biomarkers for exploring aetiology and designing new therapies.Clin Kidney J202439184952
Huang T, Bosi A, Faucon AL, Grams ME, Sjölander A, Fu EL, Xu Y, Carrero JJGLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes.JAMA Intern Med202439133509
Zoccali C, Tripepi G, Carioni P, Fu EL, Dekker F, Stel V, Jager KJ, Mallamaci F, Hymes JL, Maddux FW, Stuard SAntihypertensive Drug Treatment and the Risk for Intrahemodialysis Hypotension.Clin J Am Soc Nephrol202439012707
Fu EL, Wexler DJ, Cromer SJ, Bykov K, Paik JM, Patorno ESGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study.BMJ202438925801
Zoccali C, Tripepi G, Stel V, Fu EL, Mallamaci F, Dekker F, Jager KJBiomarkers in clinical epidemiology studies.Clin Kidney J202438915440
O'Hara DV, Janse RJ, Fu EL, Jardine MJ, Carrero JJAdherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.Diabetes Res Clin Pract202438876274
Hall RK, Kazancıoğlu R, Thanachayanont T, Wong G, Sabanayagam D, Battistella M, Ahmed SB, Inker LA, Barreto EF, Fu EL, Clase CM, Carrero JJDrug stewardship in chronic kidney disease to achieve effective and safe medication use.Nat Rev Nephrol202438491222
Fu EL, Carrero JJ, Sang Y, Evans M, Ishigami J, Inker LA, Grams ME, Levey AS, Coresh J, Ballew SHAssociation of Low Glomerular Filtration Rate With Adverse Outcomes at Older Age in a Large Population With Routinely Measured Cystatin C.Ann Intern Med202438285982
Odler B, Fu ELeGFR slope as a primary endpoint for clinical trials of CKD progression: one size fits all?Clin Kidney J202438264677
Gonzalez-Ortiz A, Clase CM, Bosi A, Fu EL, Pérez-Guillé BE, Faucon AL, Evans M, Zoccali C, Carrero JJEvaluation of the introduction of novel potassium binders in routine care; the Stockholm CREAtinine measurements (SCREAM) project.J Nephrol202438236474
Fu EL, Mastrorilli J, Bykov K, Wexler DJ, Cervone A, Lin KJ, Patorno E, Paik JMA population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disease and type 2 diabetes.Kidney Int202438101515
Fu EL, Levey AS, Inker LA, Carrero JJAuthors' Reply: Integer Cystatin C Values: Impact on Discordance Group Assignment and Accuracy of GFR-Estimating Equations.J Am Soc Nephrol202337921833
Zoccali C, Mallamaci F, Tripepi G, Fu EL, Stel VS, Dekker FW, Jager KJThe long-term benefits of early intensive therapy in chronic diseases-the legacy effect.Clin Kidney J202337915902
Fu EL, Desai RJ, Paik JM, Kim DH, Zhang Y, Mastrorilli JM, Cervone A, Lin KJComparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.Am J Kidney Dis202437839687
Fu EL, Levey AS, Coresh J, Grams ME, Faucon AL, Elinder CG, Dekker FW, Delanaye P, Inker LA, Carrero JJAccuracy of GFR estimating equations based on creatinine, cystatin C or both in routine care.Nephrol Dial Transplant202437813817
Writing Group for the CKD Prognosis Consortium, Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, Surapaneni A, Alencar de Pinho N, Anderson A, Appel LJ, Ärnlöv J, Azizi F, Bansal N, Bell S, Bilo HJG, Brunskill NJ, Carrero JJ, Chadban S, Chalmers J, Chen J, Ciemins E, Cirillo M, Ebert N, Evans M, Ferreiro A, Fu EL, Fukagawa M, Green JA, Gutierrez OM, Herrington WG, Hwang SJ, Inker LA, Iseki K, Jafar T, Jassal SK, Jha V, Kadota A, Katz R, Köttgen A, Konta T, Kronenberg F, Lee BJ, Lees J, Levin A, Looker HC, Major R, Melzer Cohen C, Mieno M, Miyazaki M, Moranne O, Muraki I, Naimark D, Nitsch D, Oh W, Pena M, Purnell TS, Sabanayagam C, Satoh M, Sawhney S, Schaeffner E, Schöttker B, Shen JI, Shlipak MG, Sinha S, Stengel B, Sumida K, Tonelli M, Valdivielso JM, van Zuilen AD, Visseren FLJ, Wang AY, Wen CP, Wheeler DC, Yatsuya H, Yamagata K, Yang JW, Young A, Zhang H, Zhang L, Levey AS, Gansevoort RTEstimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes: An Individual-Participant Data Meta-Analysis.JAMA202337787795
Xu Y, Faucon AL, Fu EL, Carrero JJRoutine care data and the benefits of GLP1 receptor agonists on slowing kidney function decline.Kidney Int202337599022
Bosi A, Clase CM, Ceriani L, Sjölander A, Fu EL, Runesson B, Chang Z, Landén M, Bellocco R, Elinder CG, Carrero JJAbsolute and Relative Risks of Kidney Outcomes Associated With Lithium vs Valproate Use in Sweden.JAMA Netw Open202337418264
Chatur S, Fu EL, Vaduganathan MInterpreting Nonrandomized Evidence for Clinical Decision Making in Cardio-Oncology.JACC CardioOncol202337397081
Carrero JJ, Fu EL, Sang Y, Ballew S, Evans M, Elinder CG, Barany P, Inker LA, Levey AS, Coresh J, Grams MEDiscordances Between Creatinine- and Cystatin C-Based Estimated GFR and Adverse Clinical Outcomes in Routine Clinical Practice.Am J Kidney Dis202337354936
Faucon AL, Fu EL, Stengel B, Mazhar F, Evans M, Carrero JJA nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality.Kidney Int202337330214
Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R, Schneeweiss S, Desai RJSodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study.Eur Heart J202337259575
Xu Y, Dong S, Fu EL, Sjölander A, Grams ME, Selvin E, Carrero JJLong-term Visit-to-Visit Variability in Hemoglobin A(1c) and Kidney-Related Outcomes in Persons With Diabetes.Am J Kidney Dis202337182597
Fu ELTarget Trial Emulation to Improve Causal Inference from Observational Data: What, Why, and How?J Am Soc Nephrol202337131279
Fu EL, Tomlinson LA, Carrero JJRenin-Angiotensin System Inhibition in Advanced CKD.N Engl J Med202337043662
Fu EL, Levey AS, Coresh J, Elinder CG, Rotmans JI, Dekker FW, Paik JM, Barany P, Grams ME, Inker LA, Carrero JJAccuracy of GFR Estimating Equations in Patients with Discordances between Creatinine and Cystatin C-Based Estimations.J Am Soc Nephrol202336995139
Fu EL, D'Andrea E, Wexler DJ, Patorno E, Paik JMSafety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD and Type 2 Diabetes: Population-Based US Cohort Study.Clin J Am Soc Nephrol202336827225
Fu EL, Kutz A, Desai RJFinerenone in chronic kidney disease and type 2 diabetes: the known and the unknown.Kidney Int202336603981
Mazhar F, Sjölander A, Fu EL, Ärnlöv J, Levey AS, Coresh J, Carrero JJEstimating the prevalence of chronic kidney disease while accounting for nonrandom testing with inverse probability weighting.Kidney Int202336462535
Alkas J, Bosi A, Sjölander A, Barany P, Elinder CG, Fu EL, Carrero JJNovel glucose-lowering drugs and the risk of acute kidney injury in routine care; the Stockholm CREAtinine Measurements (SCREAM) project.J Nephrol202336459371
Xu H, Garcia-Ptacek S, Bruchfeld A, Fu EL, Shori TD, Lindholm B, Eriksdotter M, Carrero JJAssociation between cholinesterase inhibitors and kidney function decline in patients with Alzheimer's dementia.Kidney Int202336341731
Lyu B, Sang Y, Selvin E, Chang AR, Alexander GC, Cohen CM, Coresh J, Shalev V, Chodick G, Karasik A, Carrero JJ, Fu EL, Xu Y, Grams ME, Shin JIPharmacologic Treatment of Type 2 Diabetes in the U.S., Sweden, and Israel.Diabetes Care202236282149
Carrero JJ, Fu EL, Vestergaard SV, Jensen SK, Gasparini A, Mahalingasivam V, Bell S, Birn H, Heide-Jørgensen U, Clase CM, Cleary F, Coresh J, Dekker FW, Gansevoort RT, Hemmelgarn BR, Jager KJ, Jafar TH, Kovesdy CP, Sood MM, Stengel B, Christiansen CF, Iwagami M, Nitsch DDefining measures of kidney function in observational studies using routine health care data: methodological and reporting considerations.Kidney Int202336280224
Trevisan M, Hjemdahl P, Clase CM, de Jong Y, Evans M, Bellocco R, Fu EL, Carrero JJCardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.Am J Kidney Dis202336208798
Bhatt AS, Vaduganathan M, Zhuo M, Fu EL, Solomon SD, Desai RJRisk of Acute Kidney Injury Among Older Adults With Heart Failure and With Reduced Ejection Fraction Treated With Angiotensin-Neprilysin Inhibitor vs Renin-Angiotensin System Inhibitor in Routine Clinical Care.J Card Fail202336191759
Swartling O, Yang Y, Clase CM, Fu EL, Hecking M, Hödlmoser S, Trolle-Lagerros Y, Evans M, Carrero JJSex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study.J Am Soc Nephrol202235906075
Janse RJ, Fu EL, Dahlström U, Benson L, Lindholm B, van Diepen M, Dekker FW, Lund LH, Carrero JJ, Savarese GUse of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.Eur J Heart Fail202235851740
Fu EL, Coresh J, Grams ME, Clase CM, Elinder CG, Paik J, Ramspek CL, Inker LA, Levey AS, Dekker FW, Carrero JJRemoving race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population.Nephrol Dial Transplant202335689668
Janse RJ, Fu EL, Clase CM, Tomlinson L, Lindholm B, van Diepen M, Dekker FW, Carrero JJStopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care data.Clin Kidney J202235664269
Ocak G, Khairoun M, Khairoun O, Bos WJW, Fu EL, Cramer MJ, Westerink J, Verhaar MC, Visseren FL, UCC-SMART study groupChronic kidney disease and atrial fibrillation: A dangerous combination.PLoS One202235390012
Hödlmoser S, Carrero JJ, Kurnikowski A, Fu EL, Swartling O, Winkelmayer WC, Schernhammer ES, Hecking MKidney Function, Kidney Replacement Therapy, and Mortality in Men and Women.Kidney Int Rep202235257057
Fu EL, Clase CM, Janse RJ, Lindholm B, Dekker FW, Jardine MJ, Carrero JJComparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practice.Int J Cardiol202235074492
Chesnaye NC, Stel VS, Tripepi G, Dekker FW, Fu EL, Zoccali C, Jager KJAn introduction to inverse probability of treatment weighting in observational research.Clin Kidney J202235035932
Trevisan M, Fu EL, Carrero JJReply to the letter regarding the article 'Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care'.Eur J Heart Fail202234989103
Fu EL, Evans M, Carrero JJ, Putter H, Clase CM, Caskey FJ, Szymczak M, Torino C, Chesnaye NC, Jager KJ, Wanner C, Dekker FW, van Diepen MTiming of dialysis initiation to reduce mortality and cardiovascular events in advanced chronic kidney disease: nationwide cohort study.BMJ202134844936
Xu Y, Fu EL, Clase CM, Mazhar F, Jardine MJ, Carrero JJGLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes.Kidney Int202234826514
Xu Y, Fu EL, Trevisan M, Jernberg T, Sjölander A, Clase CM, Carrero JJStopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes.Am Heart J202234610282
Trevisan M, Fu EL, Xu Y, Jager K, Zoccali C, Dekker FW, Carrero JJPharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design.Clin Kidney J202134221367
Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, Clase CM, Sjölander A, Carrero JJStopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care.Eur J Heart Fail202134196082
Fu EL, van Diepen M, Xu Y, Trevisan M, Dekker FW, Zoccali C, Jager K, Carrero JJPharmacoepidemiology for nephrologists (part 2): potential biases and how to overcome them.Clin Kidney J202133959262
Windahl K, EQUAL study investigators, Irving GF, Almquist T, Lidén MK, Stenvinkel P, Chesnaye NC, Drechsler C, Szymczak M, Krajewska M, Fu EL, Torino C, Porto G, Roderick P, Caskey FJ, Wanner C, Dekker FW, Jager KJ, Evans MPatient-Reported Measures and Lifestyle Are Associated With Deterioration in Nutritional Status in CKD Stage 4-5: The EQUAL Cohort Study.J Ren Nutr202233931314
Zhang JLH, Appelman-Dijkstra NM, Fu EL, Rotmans JI, Schepers APractice variation in the treatment of patients with renal hyperparathyroidism: a survey-based study in the Netherlands.BMC Nephrol202133892650
Clase CM, Fu EL, Jardine M, Mann JFE, Carrero JJCloth Masks May Prevent Transmission of COVID-19.Ann Intern Med202133872538
de Jong Y, Fu EL, van Diepen M, Trevisan M, Szummer K, Dekker FW, Carrero JJ, Ocak GValidation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function.Eur Heart J202133769473
Fu EL, Evans M, Clase CM, Tomlinson LA, van Diepen M, Dekker FW, Carrero JJStopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.J Am Soc Nephrol202133372009
Fu EL, Clase CM, Evans M, Lindholm B, Rotmans JI, Dekker FW, van Diepen M, Carrero JJComparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort Study.Am J Kidney Dis202133246024
Fu EL, van Diepen MComment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.Diabetes Care202033082247
Fu EL, Uijl A, Dekker FW, Lund LH, Savarese G, Carrero JJAssociation Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.Circ Heart Fail202033070637
Clase CM, Fu EL, Ashur A, Beale RCL, Clase IA, Dolovich MB, Jardine MJ, Joseph M, Kansiime G, Mann JFE, Pecoits-Filho R, Winkelmayer WC, Carrero JJForgotten Technology in the COVID-19 Pandemic: Filtration Properties of Cloth and Cloth Masks-A Narrative Review.Mayo Clin Proc202033012350
Fu EL, Janse RJ, de Jong Y, van der Endt VHW, Milders J, van der Willik EM, de Rooij ENM, Dekkers OM, Rotmans JI, van Diepen MAcute kidney injury and kidney replacement therapy in COVID-19: a systematic review and meta-analysis.Clin Kidney J202032897278
Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, Mansfield KE, Iwagami M, Smeeth L, Clase CM, Bhaskaran K, van Diepen M, Carrero JJ, Nitsch D, Tomlinson LAStopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.BMC Med202032723383
Clase CM, Fu EL, Joseph M, Beale RCL, Dolovich MB, Jardine M, Mann JFE, Pecoits-Filho R, Winkelmayer WC, Carrero JJCloth Masks May Prevent Transmission of COVID-19: An Evidence-Based, Risk-Based Approach.Ann Intern Med202032441991
Trevisan M, Fu EL, Szummer K, Norhammar A, Lundman P, Wanner C, Sjölander A, Jernberg T, Carrero JJGlucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction.Eur Heart J Cardiovasc Pharmacother202131999317
Fu EL, Trevisan M, Clase CM, Evans M, Lindholm B, Rotmans JI, van Diepen M, Dekker FW, Carrero JJAssociation of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes.Clin J Am Soc Nephrol201931395593
Fu EL, Franko MA, Obergfell A, Dekker FW, Gabrielsen A, Jernberg T, Carrero JJHigh-sensitivity C-reactive protein and the risk of chronic kidney disease progression or acute kidney injury in post-myocardial infarction patients.Am Heart J201931382219
Fu EL, Groenwold RHH, Zoccali C, Jager KJ, van Diepen M, Dekker FWMerits and caveats of propensity scores to adjust for confounding.Nephrol Dial Transplant201930215791